Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5CBNY)

• Drug Name: BIX-01294 Drug Info
• Synonyms: BIX01294; BIX 01294

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 25150857
  ChEBI ID: CHEBI:93986
  CAS Number: CAS 935693-62-2
  TTD Drug ID: DM5CBNY

Molecule-Related Drug Atlas

Drug(s) Targeting Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-366	DM1H45U	Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
UNC0642	DM7Y1SO	Discovery agent	N.A.	Investigative	[5]
UNC0638	DM4A1KJ	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Histone-lysine N-methyltransferase EHMT2 (EHMT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A-366	DM1H45U	Solid tumour/cancer	2A00-2F9Z	Preclinical	[4]
MS012	DM5AMFV	Inflammation	1A00-CA43.1	Preclinical	[1]
UNC0642	DM7Y1SO	Discovery agent	N.A.	Investigative	[5]
UNC0638	DM4A1KJ	Discovery agent	N.A.	Investigative	[6]
UNC0321	DMCVU1T	Discovery agent	N.A.	Investigative	[7]
BRD9539	DMFAVB5	Discovery agent	N.A.	Investigative	[8]

Drug(s) Affected By Interferon alpha-2 (IFNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[9]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[10]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[9]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[11]
PF-3758309	DM36PKZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
UNC0638	DM4A1KJ	Discovery agent	N.A.	Investigative	[3]

Drug(s) Affected By Interferon regulatory factor 7 (IRF7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[13]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[15]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[17]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[17]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[18]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[19]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[13]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Euchromatic histone-lysine N-methyltransferase 1 (EHMT1)	TTOFXD7	EHMT1_HUMAN	Inhibitor	[2]
Histone-lysine N-methyltransferase EHMT2 (EHMT2)	TTS6RZT	EHMT2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Interferon alpha-2 (IFNA2)	OT4GII73	IFNA2_HUMAN	Protein Interaction/Cellular Processes	[3]
Interferon regulatory factor 7 (IRF7)	OTC1A2PQ	IRF7_HUMAN	Gene/Protein Processing	[3]

References

• [1] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [2] Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81.
• [3] Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment. PLoS One. 2014 Jul 31;9(7):e103915. doi: 10.1371/journal.pone.0103915. eCollection 2014.
• [4] Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9.
• [5] Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42.
• [6] A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74.
• [7] Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57.
• [8] A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7.
• [9] Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells. J Cell Biochem. 2012 Oct;113(10):3143-52. doi: 10.1002/jcb.24191.
• [10] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [11] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [12] Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4. Oncol Rep. 2017 Nov;38(5):2705-2716. doi: 10.3892/or.2017.5989. Epub 2017 Sep 22.
• [13] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [14] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [15] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [16] Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon- inhibition. Acta Pharm Sin B. 2020 Jun;10(6):1061-1072. doi: 10.1016/j.apsb.2020.01.016. Epub 2020 Jan 31.
• [17] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [18] Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.
• [19] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.